Download Brochure
Adjuvants and novel delivery systems hold the promise of innovating vaccines by enhancing the immune response, decreasing dosage requirements, and overcoming cold chain challenges. More than just a tool for vaccine developers, Adjuvants have become an integral part of the solution for fighting disease. Lack of FDA approval for new Adjuvants presents a major hurdle for vaccine developers, as do the pressing concerns for undesirable side effects. In the Novel Vaccines’ “Adjuvants & Delivery Systems” meeting, vaccine leaders will discuss their promising work that is leading the way to Next Generation Vaccines.
Opening Keynote Presentation:
Cytokines and Toll-Like Receptor Ligands as Adjuvants to Improve the Quality as well as Quantity of T Cell Immune ResponsesJay A. Berzofsky, M.D., Ph.D., Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health
|
Talk Title to be Announced
Nathalie Garçon, Ph.D., VP & Head, Research & N. American R&D, GlaxoSmithKline Biologicals
Talk Title to be Announced
Sean Tucker, Ph.D., Founder, VP Research & CSO, Vaxart, Inc.
Talk Title to be Announced
Bali Pulendran, Ph.D., Professor, Pathology, Emory University School of Medicine
Adjuvantation of a Vaccine without Adjuvant Injection
Mei X. Wu, M.D., Ph.D., Associate Professor, Wellman Center for Photomedicines, MGH/Harvard Medical School
Clinical Safety of the ISCOMATRIX Adjuvant
Marli Watt, M.D., Clinical Safety Physician, Clinical Safety, CSL Limited
Enhancement of Response to Vaccines with the Use of an Immune Modulating Peptide, Thymosin Alpha 1
Israel Rios, M.D., CMO & Senior VP, SciClone Pharmaceuticals, Inc.
Vaccine Immune-Enhancing Delivery Systems: From Danger Signals to a Nutritive Approach in Vaccine and Adjuvant Design
Michael Vajdy, Ph.D., CEO, EpitoGenesis, Inc.
Mucosal Immunization against Vaginal Candida Infections Using Sap2 Recombinant Protein Delivered by Influenza Virosomes
Rinaldo Zurbriggen, Ph.D., Senior Program Manager, Biopharma Manufacturing, Lonza AG
Intranasal Nanoemulsion Adjuvanted Influenza Vaccine – Dose Range Efficacy and Toxicity Studies
Tarek Hamouda, M.D., Ph.D., M.B.A., Director of Vaccines, NanoBio Corp.
How VLPs Develop Their Efficacy
Thomas Stauffer, Ph.D., CEO, Pevion Biotech
Synthetic Virus-Like Particle (SVLP) Technology in Synthetic Vaccine Design
Arin Ghasparian, Ph.D., CSO, Virometix AG
Lecithin Nanoparticles as an Adjuvant for Vaccines
Zhengrong Cui, Ph.D., Associate Professor, College of Pharmacy, The University of Texas at Austin
Heterologous Prime-Boost Vaccines for HIV Vaccine Development
Shan Lu, M.D., Ph.D., Professor, Medicine, University of Massachusetts Medical School
Designing Smarter Adenoviral Vector Delivery of Vaccines: What Has Translated Successfully into Humans
Alfredo Nicosia, Ph.D., CSO, Okairos
SynCon DNA Vaccines for Emerging Infectious Diseases
Niranjan Y. Sardesai, Ph.D., Senior VP, Research & Development, Inovio Biomedical Corporation